These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 8636434)
1. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. Brugnara C; Gee B; Armsby CC; Kurth S; Sakamoto M; Rifai N; Alper SL; Platt OS J Clin Invest; 1996 Mar; 97(5):1227-34. PubMed ID: 8636434 [TBL] [Abstract][Full Text] [Related]
2. Treatment with oral clotrimazole blocks Ca(2+)-activated K+ transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease. De Franceschi L; Saadane N; Trudel M; Alper SL; Brugnara C; Beuzard Y J Clin Invest; 1994 Apr; 93(4):1670-6. PubMed ID: 7512989 [TBL] [Abstract][Full Text] [Related]
3. Oral administration of clotrimazole and blockade of human erythrocyte Ca(++)-activated K+ channel: the imidazole ring is not required for inhibitory activity. Brugnara C; Armsby CC; Sakamoto M; Rifai N; Alper SL; Platt O J Pharmacol Exp Ther; 1995 Apr; 273(1):266-72. PubMed ID: 7714775 [TBL] [Abstract][Full Text] [Related]
4. Erythrocyte dehydration in pathophysiology and treatment of sickle cell disease. Brugnara C Curr Opin Hematol; 1995 Mar; 2(2):132-8. PubMed ID: 9371983 [TBL] [Abstract][Full Text] [Related]
5. ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Stocker JW; De Franceschi L; McNaughton-Smith GA; Corrocher R; Beuzard Y; Brugnara C Blood; 2003 Mar; 101(6):2412-8. PubMed ID: 12433690 [TBL] [Abstract][Full Text] [Related]
6. Additive in vitro effects of anti-sickling drugs. Stuart J; Mojiminiyi FB; Stone PC; Culliford SJ; Ellory JC Br J Haematol; 1994 Apr; 86(4):820-3. PubMed ID: 7918079 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of Ca(2+)-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. Brugnara C; de Franceschi L; Alper SL J Clin Invest; 1993 Jul; 92(1):520-6. PubMed ID: 8326017 [TBL] [Abstract][Full Text] [Related]
8. A new therapeutic approach for sickle cell disease. Blockade of the red cell Ca(2+)-activated K+ channel by clotrimazole. Brugnara C; De Franceschi L; Armsby CC; Saadane N; Trudel M; Beuzard Y; Rittenhouse A; Rifai N; Platt O; Alper SL Ann N Y Acad Sci; 1995 Jul; 763():262-71. PubMed ID: 7677336 [No Abstract] [Full Text] [Related]
9. Combined genetic disruption of K-Cl cotransporters and Gardos channel KCNN4 rescues erythrocyte dehydration in the SAD mouse model of sickle cell disease. Shmukler BE; Rivera A; Bhargava P; Nishimura K; Hsu A; Kim EH; Trudel M; Rust MB; Hubner CA; Brugnara C; Alper SL Blood Cells Mol Dis; 2019 Nov; 79():102346. PubMed ID: 31352162 [TBL] [Abstract][Full Text] [Related]
10. Effect of 1-chloro-2,4-dinitrobenzene on K+ transport in normal and sickle human red blood cells. Muzyamba MC; Gibson JS J Physiol; 2003 Mar; 547(Pt 3):903-11. PubMed ID: 12576491 [TBL] [Abstract][Full Text] [Related]
11. Sickle cell disease: from membrane pathophysiology to novel therapies for prevention of erythrocyte dehydration. Brugnara C J Pediatr Hematol Oncol; 2003 Dec; 25(12):927-33. PubMed ID: 14663274 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic strategies for prevention of sickle cell dehydration. Brugnara C Blood Cells Mol Dis; 2001; 27(1):71-80. PubMed ID: 11358364 [TBL] [Abstract][Full Text] [Related]
13. [Clinical trials of new therapeutic pharmacology for sickle cell disease]. Brugnara C; de Franceschi L Sante; 2006; 16(4):263-8. PubMed ID: 17446160 [TBL] [Abstract][Full Text] [Related]
14. Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. McNaughton-Smith GA; Burns JF; Stocker JW; Rigdon GC; Creech C; Arrington S; Shelton T; de Franceschi L J Med Chem; 2008 Feb; 51(4):976-82. PubMed ID: 18232633 [TBL] [Abstract][Full Text] [Related]
15. N-acetylcysteine and clotrimazole inhibit sickle erythrocyte dehydration induced by 1-chloro-2,4-dinitrobenzene. Shartava A; Shah AK; Goodman SR Am J Hematol; 1999 Sep; 62(1):19-24. PubMed ID: 10467272 [TBL] [Abstract][Full Text] [Related]
16. Combination therapy of erythropoietin, hydroxyurea, and clotrimazole in a beta thalassemic mouse: a model for human therapy. de Franceschi L; Rouyer-Fessard P; Alper SL; Jouault H; Brugnara C; Beuzard Y Blood; 1996 Feb; 87(3):1188-95. PubMed ID: 8562946 [TBL] [Abstract][Full Text] [Related]
17. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). Ataga KI; Reid M; Ballas SK; Yasin Z; Bigelow C; James LS; Smith WR; Galacteros F; Kutlar A; Hull JH; Stocker JW; Br J Haematol; 2011 Apr; 153(1):92-104. PubMed ID: 21323872 [TBL] [Abstract][Full Text] [Related]
18. Differences in the actions of some blockers of the calcium-activated potassium permeability in mammalian red cells. Benton DC; Roxburgh CJ; Ganellin CR; Shiner MA; Jenkinson DH Br J Pharmacol; 1999 Jan; 126(1):169-78. PubMed ID: 10051133 [TBL] [Abstract][Full Text] [Related]